凱龍股份(002783.SZ):2022年擬向相關金融機構申請授信額度預計為40.6億元
格隆匯12月8日丨凱龍股份(002783.SZ)公佈,公司第八屆董事會第十次會議決議,審議通過《關於公司及控股子公司2022年向金融機構申請授信及融資計劃的議案》 ,該議案尚需提交股東大會審議。
根據公司生產經營需要,2022年公司及控股子公司擬向相關金融機構申請授信額度預計為40.6億元。同時公司及控股子公司可在以上各金融機構年度綜合授信餘額內,根據貸款進度安排選擇辦理銀行承兑匯票和開立信用證等業務。對於2022年新增的併購貸款、通過銀行間協會發行超短融、短融和中期票據等融資業務一事一議,單獨審批。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.